Shortcomings of Randomised Controlled Trials, such as lack of power, size, length and cost, limit medical innovation. Clinical trials are evolving to facilitate advances in personalised and targeted medicine to benefit patients and identify true benefits. The session will look at how clinical trials have evolved to address issues like personalised and targeted medicine. It will discuss techniques such as: adaptive trial design; targeted recruitment; patient-reported outcomes etc. It will also explore how to interpret these new types of trials and consider statistical techniques and operational procedures. This session is essential for roles that interpret and communicate scientific data and clinical research.
Chairperson: Katarina Kelin, MD, MBA, Associate Medical Director, Eli Lilly Australia and New Zealand